Finally, irrespective of sGSN, it is important to note that cDC1s and/or DNGR-1-mediated cross-presentation might be dispensable for immunity to some cancer types (Asano et al., 2011; Gilfillan et al., 2018; Ma et al., 2013). Here, CLEC9A is linked to cancer.